BMS Adds To String Of Pearls: $470 Mil. Deal With French Biotech Brings Innate Immunity Approach Into Its R&D Pipeline

BMS deal with Innate Pharma strengthens the U.S. company's focus on cancer immunotherapy, and adds fillip to biotech companies in France.